$PHIO
Phio Pharmaceuticals Corp.

2014 Q2 Form 10-Q Financial Statement

#000119312514198000 Filed on May 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $12.00K $29.00K $53.00K
YoY Change -94.67% -45.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $850.0K $840.0K $12.93M
YoY Change -107.54% -93.5% 1624.0%
% of Gross Profit
Research & Development $1.183M $1.476M $13.77M
YoY Change -2.47% -89.28% 1093.33%
% of Gross Profit
Depreciation & Amortization $20.00K $22.00K $26.00K
YoY Change 0.0% -15.38% -35.0%
% of Gross Profit
Operating Expenses $2.033M $2.319M $14.45M
YoY Change -7.17% -83.95% 658.37%
Operating Profit -$2.021M -$2.290M -$14.39M
YoY Change 2.85% -84.09% 655.59%
Interest Expense $5.000K $6.000K $0.00
YoY Change 25.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $15.00K -$3.000K
YoY Change -400.0%
Pretax Income -$2.010M -$2.280M -$14.40M
YoY Change 2.55% -84.17% 646.11%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.006M -$2.284M -$14.40M
YoY Change 2.29% -84.14% 647.51%
Net Earnings / Revenue -16716.67% -7875.86% -27164.15%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.263B -$1.761B -$15.20B
COMMON SHARES
Basic Shares Outstanding 14.03M shares 13.37M shares 321.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.91M $12.01M $19.64M
YoY Change -32.29% -38.85% 5355.56%
Cash & Equivalents $11.91M $9.010M $19.64M
Short-Term Investments $0.00 $3.000M
Other Short-Term Assets $420.0K $280.0K $150.0K
YoY Change 61.54% 86.67% 150.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.33M $12.29M $19.80M
YoY Change -30.93% -37.94% 1860.2%
LONG-TERM ASSETS
Property, Plant & Equipment $204.0K $155.0K $172.0K
YoY Change 38.78% -9.88% -46.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.00K $20.00K $0.00
YoY Change
Total Long-Term Assets $222.0K $173.0K $174.0K
YoY Change 51.02% -0.57% -45.63%
TOTAL ASSETS
Total Short-Term Assets $12.33M $12.29M $19.80M
Total Long-Term Assets $222.0K $173.0K $174.0K
Total Assets $12.55M $12.46M $19.97M
YoY Change -30.26% -37.62% 1401.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $293.0K $277.0K $366.0K
YoY Change -18.16% -24.32% -51.2%
Accrued Expenses $682.0K $1.024M $1.126M
YoY Change -25.3% -9.06% 108.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $1.053M $1.390M $1.958M
YoY Change -30.26% -29.01% -6.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.053M $1.390M $1.958M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.050M $1.390M $1.958M
YoY Change -30.46% -29.01% -36.84%
SHAREHOLDERS EQUITY
Retained Earnings -$42.37M
YoY Change
Common Stock $1.000K $1.000K $32.00K
YoY Change 0.0% -96.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.562M $6.219M $8.118M
YoY Change
Total Liabilities & Shareholders Equity $12.55M $12.46M $19.97M
YoY Change -30.26% -37.62% 1401.65%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$2.006M -$2.284M -$14.40M
YoY Change 2.29% -84.14% 647.51%
Depreciation, Depletion And Amortization $20.00K $22.00K $26.00K
YoY Change 0.0% -15.38% -35.0%
Cash From Operating Activities -$2.020M -$2.380M -$1.128M
YoY Change -1.46% 110.99% -6.7%
INVESTING ACTIVITIES
Capital Expenditures -$70.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.010M
YoY Change -133.44%
Cash From Investing Activities $2.940M
YoY Change -132.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $15.65M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.980M 15.64M
YoY Change 19700.0% 1448.91%
NET CHANGE
Cash From Operating Activities -2.020M -2.380M -1.128M
Cash From Investing Activities 2.940M
Cash From Financing Activities 1.980M 15.64M
Net Change In Cash 2.900M -2.380M 14.52M
YoY Change -126.27% -116.4% -7394.47%
FREE CASH FLOW
Cash From Operating Activities -$2.020M -$2.380M -$1.128M
Capital Expenditures -$70.00K
Free Cash Flow -$1.950M -$2.380M -$1.128M
YoY Change -4.88% 110.99% -6.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14027167 shares
CY2013Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19643000
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13427167 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1159004 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13427167 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.48
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2581268 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.32
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1024000
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41964000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
277000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1390000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
6219000
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
89000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12459000
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
CY2014Q1 us-gaap Assets Current
AssetsCurrent
12286000
CY2014Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
18000
CY2014Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2014Q1 us-gaap Assets
Assets
12459000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9010000
CY2014Q1 us-gaap Short Term Investments
ShortTermInvestments
3000000
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1341673
CY2014Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
40366000
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
226000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2879168
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
155000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5127000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11788045 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11788045 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.47
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2556269 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1795000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40969000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
163000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2076000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
4942000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14938000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
14743000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
118000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2013Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
18000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2013Q4 us-gaap Assets
Assets
14938000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11390000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
3000000
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
38082000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
303000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2013Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6496095 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1128000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.76
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
pure
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26255213 shares
CY2013Q1 us-gaap Revenues
Revenues
53000
CY2013Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110000
CY2013Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
628000
CY2013Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
CY2013Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2013Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17944000
CY2013Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2013Q1 us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
CY2013Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
CY2013Q1 us-gaap Stock Issued1
StockIssued1
CY2013Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
CY2013Q1 us-gaap Revenue From Grants
RevenueFromGrants
53000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14394000
CY2013Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
CY2013Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
CY2013Q1 us-gaap Interest Paid
InterestPaid
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-14397000
CY2013Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
CY2013Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3000
CY2013Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2013Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2013Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
CY2013Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
676000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15644000
CY2013Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
170000
CY2013Q1 us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
CY2013Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
12250000
CY2013Q1 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
CY2013Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
CY2013Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
359000
CY2013Q1 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
628000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14516000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-54000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-50000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15647000
CY2013Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
3547000
CY2013Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13771000
CY2013Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
CY2013Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
CY2013Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3547000
CY2013Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
CY2013Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
14447000
CY2013Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
CY2013Q1 rxii Other Significant Noncash Transaction Value Of Parent Company Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses
OtherSignificantNoncashTransactionValueOfParentCompanyRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses
CY2013Q1 rxii Allocation Of Management Expenses
AllocationOfManagementExpenses
CY2013Q1 rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
CY2013Q1 rxii Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants
FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants
CY2013Q1 rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
CY2013Q1 rxii Value Of Parent Company Restricted Stock Units Issued In Lieu Of Bonuses Included In Accrued Expenses
ValueOfParentCompanyRestrictedStockUnitsIssuedInLieuOfBonusesIncludedInAccruedExpenses
CY2013Q1 rxii Fair Value Of Parent Company Stock Options Modified
FairValueOfParentCompanyStockOptionsModified
CY2013Q1 rxii Parent Issuance Of Stock And Warrants For Services Or Claims
ParentIssuanceOfStockAndWarrantsForServicesOrClaims
CY2013Q1 rxii Parent Research And Development Intangibles Purchased From Others
ParentResearchAndDevelopmentIntangiblesPurchasedFromOthers
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001533040
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0296 pure
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2014Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M10D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P9Y9M29D
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12616086 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.02
CY2014Q1 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
Three months or less
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.62
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2380000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
24999 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0664 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25670763 shares
CY2014Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.033 pure
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Uses of estimates in preparation of financial statements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
CY2014Q1 us-gaap Revenues
Revenues
29000
CY2014Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-77000
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
491000
CY2014Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
CY2014Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2014Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4039000
CY2014Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2014Q1 us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
CY2014Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
3000000
CY2014Q1 us-gaap Stock Issued1
StockIssued1
CY2014Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
CY2014Q1 us-gaap Revenue From Grants
RevenueFromGrants
29000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2290000
CY2014Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
6000
CY2014Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
CY2014Q1 us-gaap Interest Paid
InterestPaid
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2284000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
CY2014Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
CY2014Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2014Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2014Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
CY2014Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
843000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2014Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
168000
CY2014Q1 us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
CY2014Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
CY2014Q1 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
CY2014Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
CY2014Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
672000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-29000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
1755000
CY2014Q1 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
491000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2380000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-771000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
114000
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1476000
CY2014Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000
CY2014Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
CY2014Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1755000
CY2014Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
CY2014Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2319000
CY2014Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
CY2014Q1 rxii Other Significant Noncash Transaction Value Of Parent Company Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses
OtherSignificantNoncashTransactionValueOfParentCompanyRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses
CY2014Q1 rxii Allocation Of Management Expenses
AllocationOfManagementExpenses
CY2014Q1 rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
CY2014Q1 rxii Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants
FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants
CY2014Q1 rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
CY2014Q1 rxii Value Of Parent Company Restricted Stock Units Issued In Lieu Of Bonuses Included In Accrued Expenses
ValueOfParentCompanyRestrictedStockUnitsIssuedInLieuOfBonusesIncludedInAccruedExpenses
CY2014Q1 rxii Fair Value Of Parent Company Stock Options Modified
FairValueOfParentCompanyStockOptionsModified
CY2014Q1 rxii Parent Issuance Of Stock And Warrants For Services Or Claims
ParentIssuanceOfStockAndWarrantsForServicesOrClaims
CY2014Q1 rxii Parent Research And Development Intangibles Purchased From Others
ParentResearchAndDevelopmentIntangiblesPurchasedFromOthers

Files In Submission

Name View Source Status
0001193125-14-198000-index-headers.html Edgar Link pending
0001193125-14-198000-index.html Edgar Link pending
0001193125-14-198000.txt Edgar Link pending
0001193125-14-198000-xbrl.zip Edgar Link pending
d703445d10q.htm Edgar Link pending
d703445dex311.htm Edgar Link pending
d703445dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20140331.xml Edgar Link completed
rxii-20140331.xsd Edgar Link pending
rxii-20140331_cal.xml Edgar Link unprocessable
rxii-20140331_def.xml Edgar Link unprocessable
rxii-20140331_lab.xml Edgar Link unprocessable
rxii-20140331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending